NERV
Minerva Neurosciences, Inc.
Biotechnology
Market Cap$32M
5Y Perf.-84.4%
Build Your Comparison
Side-by-side financial analysisNERV
NRXP
Try popular comparisons:
Stock Comparison
NERV vs NRXP
Revenue, margins, valuation, and 5-year total return — side by side.
NRXP
NRx Pharmaceuticals, Inc.
Biotechnology
Market Cap$66M
5Y Perf.-96.3%
NERV vs NRXP — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  NERV |  NRXP |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $32M | $66M |
| Revenue (TTM) | $0.00 | $2M |
| Net Income (TTM) | $-415M | $-25M |
| Gross Margin | — | 37.1% |
| Operating Margin | — | -7.5% |
| Total Debt | $65M | $631K |
| Cash & Equiv. | $82M | $8M |
NERV vs NRXP — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
NERV
NRXP
| Stock | Jun 20 | Jun 26 | Return |
|---|---|---|---|
| Minerva Neuroscienc… (NERV) | 100 | 15.6 | -84.4% |
| NRx Pharmaceuticals… (NRXP) | 100 | 3.7 | -96.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NERV vs NRXP
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: NERV leads in 3 of 5 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. NRx Pharmaceuticals, Inc. is the stronger pick specifically for operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
🥇NERV emerged as the overall leader. Track its performance:
NERV
Minerva Neurosciences, Inc.
The Income Pick
NERV carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 1.28
- -94.4% 10Y total return vs NRXP's -96.0%
- Lower volatility, beta 1.28, current ratio 36.29x
Best for: income & stability and long-term compounding
NRXP
NRx Pharmaceuticals, Inc.
The Growth Play
NRXP is the clearest fit if your priority is growth exposure.
- EPS growth 43.9%
- -219.6% ROA vs NERV's -6.6%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  NERV | 121.0% revenue growth vs NRXP's -7.6% |
| Stability / Safety | NERV | Beta 1.28 vs NRXP's 2.05 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | NERV | +152.0% vs NRXP's +11.6% |
| Efficiency (ROA) |  NRXP | -219.6% ROA vs NERV's -6.6% |
NERV vs NRXP — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
NERV vs NRXP — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLNRXPLAGGINGNERV
NERVMinerva Neurosciences…
0leads
NRXPNRx Pharmaceuticals, …
2leads
6 Total Categories
CATEGORYLEADERvs NERVMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
—
—
Valuation MetricsMultiples, price ratios, and targets
NRXP1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
NRXP3/4
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Insufficient data to determine a leader in this category.
Income & Cash Flow (Last 12 Months)
NRXP and NERV operate at a comparable scale, with $2M and $0 in trailing revenue.
| Metric | NERVMinerva Neuroscie… | NRXPNRx Pharmaceutica… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $2M |
| EBITDAEarnings before interest/tax | -$28M | -$31M |
| Net IncomeAfter-tax profit | -$415M | -$25M |
| Free Cash FlowCash after capex | -$5.4B | -$15M |
| Gross MarginGross profit ÷ Revenue | — | +37.1% |
| Operating MarginEBIT ÷ Revenue | — | -7.5% |
| Net MarginNet income ÷ Revenue | — | -10.7% |
| FCF MarginFCF ÷ Revenue | — | -6.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | — | +87.0% |
Insufficient data to determine a leader in this category.
Valuation Metrics
NRXP leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | NERVMinerva Neuroscie… | NRXPNRx Pharmaceutica… |
|---|---|---|
| Market CapShares × price | $32M | $66M |
| Enterprise ValueMkt cap + debt − cash | $14M | $59M |
| Trailing P/EPrice ÷ TTM EPS | -0.13x | -2.87x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 54.19x |
| Price / BookPrice ÷ Book value/share | — | — |
| Price / FCFMarket cap ÷ FCF | — | — |
NRXP leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
NRXP leads this category, winning 3 of 4 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), NRXP scores 6/9 vs NERV's 2/9, reflecting solid financial health.
| Metric | NERVMinerva Neuroscie… | NRXPNRx Pharmaceutica… |
|---|---|---|
| ROE (TTM)Return on equity | — | — |
| ROA (TTM)Return on assets | -6.6% | -2.2% |
| ROICReturn on invested capital | — | — |
| ROCEReturn on capital employed | -23.2% | — |
| Piotroski ScoreFundamental quality 0–9 | 2 | 6 |
| Debt / EquityFinancial leverage | — | — |
| Net DebtTotal debt minus cash | -$17M | -$7M |
| Cash & Equiv.Liquid assets | $82M | $8M |
| Total DebtShort + long-term debt | $65M | $631,000 |
| Interest CoverageEBIT ÷ Interest expense | — | -34.34x |
NRXP leads this category, winning 3 of 4 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — NERV and NRXP each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NERV five years ago would be worth $1,905 today (with dividends reinvested), compared to $213 for NRXP. Over the past 12 months, NERV leads with a +152.0% total return vs NRXP's +11.6%. The 3-year compound annual growth rate (CAGR) favors NRXP at -10.5% vs NERV's -12.1% — a key indicator of consistent wealth creation.
| Metric | NERVMinerva Neuroscie… | NRXPNRx Pharmaceutica… |
|---|---|---|
| YTD ReturnYear-to-date | +15.1% | +46.6% |
| 1-Year ReturnPast 12 months | +152.0% | +11.6% |
| 3-Year ReturnCumulative with dividends | -32.2% | -28.2% |
| 5-Year ReturnCumulative with dividends | -81.0% | -97.9% |
| 10-Year ReturnCumulative with dividends | -94.4% | -96.0% |
| CAGR (3Y)Annualised 3-year return | -12.1% | -10.5% |
Evenly matched — NERV and NRXP each lead in 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — NERV and NRXP each lead in 1 of 2 comparable metrics.
Risk & Volatility
NERV is the less volatile stock with a 1.28 beta — it tends to amplify market swings less than NRXP's 2.05 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NRXP currently trades 76.0% from its 52-week high vs NERV's 36.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | NERVMinerva Neuroscie… | NRXPNRx Pharmaceutica… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.28x | 2.05x |
| 52-Week HighHighest price in past year | $12.46 | $5.05 |
| 52-Week LowLowest price in past year | $1.57 | $1.62 |
| % of 52W HighCurrent price vs 52-week peak | +36.2% | +76.0% |
| RSI (14)Momentum oscillator 0–100 | 37.4 | 55.1 |
| Avg Volume (50D)Average daily shares traded | 154K | 1.3M |
Evenly matched — NERV and NRXP each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | NERVMinerva Neuroscie… | NRXPNRx Pharmaceutica… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — |
| Price TargetConsensus 12-month target | $5.00 | — |
| # AnalystsCovering analysts | 7 | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
NRXP leads in 2 of 6 categories — strongest in Valuation Metrics and Profitability & Efficiency. 2 categories are tied.
Best OverallNRx Pharmaceuticals, Inc. (NRXP)Leads 2 of 6 categories
Loading custom metrics...
NERV vs NRXP: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is NERV or NRXP a better buy right now?
Analysts rate Minerva Neurosciences, Inc.
(NERV) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — NERV or NRXP?
Over the past 5 years, Minerva Neurosciences, Inc.
(NERV) delivered a total return of -81. 0%, compared to -97. 9% for NRx Pharmaceuticals, Inc. (NRXP). Over 10 years, the gap is even starker: NERV returned -94. 4% versus NRXP's -96. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — NERV or NRXP?
By beta (market sensitivity over 5 years), Minerva Neurosciences, Inc.
(NERV) is the lower-risk stock at 1. 28β versus NRx Pharmaceuticals, Inc. 's 2. 05β — meaning NRXP is approximately 60% more volatile than NERV relative to the S&P 500.
04Which is growing faster — NERV or NRXP?
On earnings-per-share growth, the picture is similar: NRx Pharmaceuticals, Inc.
grew EPS 43. 9% year-over-year, compared to -183. 5% for Minerva Neurosciences, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — NERV or NRXP?
Minerva Neurosciences, Inc.
(NERV) is the more profitable company, earning 0. 0% net margin versus -23. 4% for NRx Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NERV leads at 0. 0% versus -1324. 4% for NRXP. At the gross margin level — before operating expenses — NRXP leads at 58. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — NERV or NRXP?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is NERV or NRXP better for a retirement portfolio?
For long-horizon retirement investors, Minerva Neurosciences, Inc.
(NERV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 28)). NRx Pharmaceuticals, Inc. (NRXP) carries a higher beta of 2. 05 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NERV: -94. 4%, NRXP: -96. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between NERV and NRXP?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.